论文部分内容阅读
目的:探讨Polo样激酶1(plk1)、p34cdc2在卵巢上皮源性肿瘤组织中的表达及与卵巢癌各临床病理特征的关系。方法:免疫组化SP法对正常卵巢及卵巢上皮良性肿瘤、卵巢癌组织中的plk1、p34cdc2进行检测。结果:卵巢癌组织中的plk1、p34cdc2阳性表达率分别为80.8%(38/47)和63.8%(30/47)。plk1与p34cdc2的表达在正常卵巢、卵巢上皮良性肿瘤及卵巢癌组织中呈明显递增趋势,且两者在卵巢癌组织中的表达显著高于其余2组,P均<0.01。plk1的表达与卵巢癌的组织学分级、临床分期及病理学类型无关;p34cdc2的阳性表达与卵巢癌的组织学分级、临床分期呈明显相关。在47例卵巢癌组织中,plk1的表达与p34cdc2的表达呈正相关,r=0.388,P=0.004。结论:plk1和p34cdc2的高表达可能与卵巢癌的发生、发展密切相关,可望成为卵巢癌治疗的理想靶点。
Objective: To investigate the expression of Polya-like kinase 1 (plk1) and p34cdc2 in ovarian epithelial tumor and its relationship with the clinicopathological features of ovarian cancer. Methods: Immunohistochemical SP method was used to detect plk1 and p34cdc2 in normal ovarian and ovarian epithelial benign tumors and ovarian cancer tissues. Results: The positive rates of plk1 and p34cdc2 in ovarian cancer were 80.8% (38/47) and 63.8% (30/47), respectively. The expression of plk1 and p34cdc2 in normal ovary, benign epithelial ovarian cancer and ovarian cancer showed a significant increasing trend, and both in ovarian cancer tissue was significantly higher than the other two groups, P <0.01. The expression of plk1 was not associated with the histological grade, clinical stage and pathological type of ovarian cancer. The positive expression of p34cdc2 was correlated with the histological grade and clinical stage of ovarian cancer. In 47 cases of ovarian cancer, the expression of plk1 was positively correlated with the expression of p34cdc2 (r = 0.388, P = 0.004). Conclusion: The overexpression of plk1 and p34cdc2 may be closely related to the occurrence and development of ovarian cancer, and may be an ideal target for the treatment of ovarian cancer.